Clinic Roundup

• Transition Therapeutics Inc., of Toronto, reported that its licensing partner, Elan Corp. plc, of Dublin, Ireland, has commenced a Phase II trial of oral ELND005 (scyllo-inositol) as an adjunctive maintenance treatment in patients with bipolar I disorder to delay the time to occurrence of mood episodes.